Recombinant vaccines against leptospirosis
- PMID: 22048111
- DOI: 10.4161/hv.7.11.17944
Recombinant vaccines against leptospirosis
Abstract
Leptospirosis is an important neglected infectious disease that occurs in urban environments, as well as in rural regions worldwide. Rodents, the principal reservoir hosts of pathogenic Leptospira spp., and other infected animals shed the bacteria in their urine. During occupational or even recreational activities, humans that come into direct contact with infected animals or with a contaminated environment, particularly water, are at risk of infection. Prevention of urban leptospirosis is largely dependent on sanitation measures that are often difficult to implement, especially in developing countries. Vaccination with inactivated whole-cell preparations (bacterins) has limited efficacy due to the wide antigenic variation of the pathogen. Intensive efforts towards developing improved recombinant vaccines are ongoing. During the last decade, many reports on the evaluation of recombinant vaccines have been published. Partial success has been obtained with some surface-exposed protein antigens. The combination of protective antigens and new adjuvants or delivery systems may result in the much-needed effective vaccine.
Similar articles
-
Comparison of Immunoprotection of Leptospira Recombinant Proteins with conventional vaccine in experimental animals.Indian J Exp Biol. 2015 Dec;53(12):779-85. Indian J Exp Biol. 2015. PMID: 26742322
-
LigB subunit vaccine confers sterile immunity against challenge in the hamster model of leptospirosis.PLoS Negl Trop Dis. 2017 Mar 16;11(3):e0005441. doi: 10.1371/journal.pntd.0005441. eCollection 2017 Mar. PLoS Negl Trop Dis. 2017. PMID: 28301479 Free PMC article.
-
Reverse Vaccinology: An Approach for Identifying Leptospiral Vaccine Candidates.Int J Mol Sci. 2017 Jan 14;18(1):158. doi: 10.3390/ijms18010158. Int J Mol Sci. 2017. PMID: 28098813 Free PMC article. Review.
-
Evaluation of different ways of presenting LipL32 to the immune system with the aim of developing a recombinant vaccine against leptospirosis.Can J Microbiol. 2007 Apr;53(4):472-9. doi: 10.1139/w06-138. Can J Microbiol. 2007. PMID: 17612601
-
DNA vaccines against leptospirosis: A literature review.Vaccine. 2017 Oct 9;35(42):5559-5567. doi: 10.1016/j.vaccine.2017.08.067. Epub 2017 Sep 4. Vaccine. 2017. PMID: 28882437 Review.
Cited by
-
Improvement the expression and purification of Loa22: a lipoprotein with OmpA domain from pathogenic Leptospira serovars.Iran J Microbiol. 2023 Oct;15(5):674-684. doi: 10.18502/ijm.v15i5.13873. Iran J Microbiol. 2023. PMID: 37941886 Free PMC article.
-
The leptospiral OmpA-like protein (Loa22) is a surface-exposed antigen that elicits bactericidal antibody against heterologous Leptospira.Vaccine X. 2023 Sep 1;15:100382. doi: 10.1016/j.jvacx.2023.100382. eCollection 2023 Dec. Vaccine X. 2023. PMID: 37727366 Free PMC article.
-
Leptospirosis Risk among Occupational Groups in Brazil, 2010-2015.Am J Trop Med Hyg. 2023 Jul 3;109(2):376-386. doi: 10.4269/ajtmh.21-0181. Print 2023 Aug 2. Am J Trop Med Hyg. 2023. PMID: 37400068 Free PMC article.
-
Sph2(176-191) and Sph2(446-459): Identification of B-Cell Linear Epitopes in Sphingomyelinase 2 (Sph2), Naturally Recognized by Patients Infected by Pathogenic Leptospires.Vaccines (Basel). 2023 Feb 4;11(2):359. doi: 10.3390/vaccines11020359. Vaccines (Basel). 2023. PMID: 36851237 Free PMC article.
-
Analysis of LruC lipoprotein and identification of peptides candidates for vaccine development and diagnosis of leptospirosis.PLoS One. 2023 Feb 6;18(2):e0281344. doi: 10.1371/journal.pone.0281344. eCollection 2023. PLoS One. 2023. PMID: 36745643 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical
Miscellaneous